GlaxoSmithKline (GSK) has told us it is having problems with the supply of Lamictal. This is due to manufacturing problems.
Actavis has discontinued its version of lamotrigine and there are no stocks left. This applies to both the dispersible and non-dispersible tablets.
GlaxoSmithKline (GSK), the manufacturer of retigabine (brand name Trobalt), has announced it will permanently stop making this medicine from June 2017.
Actavis have told us that they no longer have any supplies of lamotrigine.
They are unable to say if and when they may stock lamotrigine in the future.
Unlicensed Special (as Midazolam Maleate): There is a fault with around half of the bottles from batch number 73234. The neck of the adaptor, which reduces the size of the opening to accommodate the oral syringes, is the wrong size and does not fit the syringes.
We have checked stock levels with Actavis. The 5 mg tubes will be out of stock until November 2016. There are limited supplies of the 10 mg tubes in stock. Once these have run out Actavis do not know when they will be back in stock.
There is an error on the barcode of some batches of Primidone 50 mg tablets made by SERB. When the barcode is scanned, it says the tablets are 250 mg, not 50 mg tablets as it should.
The following medicines are currently out of stock:
- Carbagen 100 mg – 28 tablet and 84 tablet packs
- Carbagen 200 mg – 28 tablet packs
Some packs of Teva pregabalin 75 mg have the wrong strength printed on part of the pack. On affected packs the strength is printed incorrectly, as 25 mg instead of 75 mg, in one position on the foil (see picture below).
The Medicines and Healthcare products Regulatory Authority (MHRA) has suspended the licence for the following epilepsy medicines made by Dr Reddy's Laboratories (UK) Limited:
- Levetiracetam Dr Reddy's 250 mg film-coated tablets
- Levetiracetam Dr Reddy's 500 mg film-coated tablets
- Levetiracetam Dr Reddy's 750 mg film-coated tablets
- Levetiracetam Dr Reddy's 1000 mg film-coated tablets